Adjuvant @entity2213 treatment in XXXX : which risk stratification criteria and for how long? A case report.

@entity1 @entity2213 @entity5 @entity674
UNASSIGNED: @entity2213 mesylate is approved for the adjuvant treatment of KIT-positive @entity674 ( @entity674 ) following surgical resection. However, uncertainty remains in terms of @entity1 eligibility for adjuvant treatment and the optimal duration of treatment. Here, we present two challenging @entity1 cases encountered in clinical practice that highlight the ambiguity in the current recommendations for adjuvant @entity2213 in @entity674 and discuss our approaches and rationales for treatment. The first case involves a 36-year-old @entity1 with a 7   cm duodenal @entity674 and possible @entity5 rupture during surgical resection. This @entity1 's risk of @entity674 recurrence was either intermediate or high depending on which risk stratification criteria were used. The @entity1 was treated with adjuvant @entity2213 for 3 years and experienced disease recurrence 14 months after the completion of treatment. @entity2213 treatment was reintroduced, and the @entity1 is in partial response 17 months later. The second case involves a 46-year-old @entity1 at high risk of recurrence following surgical resection. Adjuvant treatment with @entity2213 was initiated. After considering the @entity1 's initial high risk and good side-effect profile, the decision was made to continue adjuvant @entity2213 treatment for 5 years. As of May 2013, the @entity1 has been receiving continuous @entity2213 treatment for 52 months, with no sign of progression. These reports exemplify the challenges faced in clinical practice because of uncertainties in optimal risk stratification criteria and duration of treatment. They stress the importance of individualized treatment and shared decision making between the physician and the @entity1 .
